Bio-Techne opens GMP manufacturing facility

By The Science Advisory Board staff writers

September 30, 2020 -- Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale production of Escherichia coli-derived recombinant proteins for cell and gene-modified therapy workflows.

Chimeric antigen receptor (CAR) T-cell therapies and stem cell therapies have significantly increased the demand for GMP-grade recombinant proteins, which Bio-Techne plans to meet with the opening of the facility. The company invested $50 million to build and outfit the plant with advanced manufacturing and quality control technologies.

The facility houses multiple fermenters and purification suites and is expected to begin commercial production in early 2021, following validation procedures.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here